Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
These findings further characterize a mechanism by which gefitinib treatment of NSCLC harboring EGFR(L858R) leads to a dramatic response to gefitinib.
|
15492241 |
2004 |
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Here, we show that L858R and deletion mutant EGFR proteins found in NSCLC interact with the chaperone and are sensitive to degradation following Hsp90 inhibition.
|
16024644 |
2005 |
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our patient supports the proposition that somatic mutation L858R in exon 21 of the EGFR gene accounts for complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung.
|
16027522 |
2005 |
Adenocarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The L858R mutation was significantly correlated with gender (women versus men, P < 0.0001), Brinkman index (600 < or = versus 600, P = 0.001), pathologic subtypes (adenocarcinoma versus nonadenocarcinoma, P = 0.007), and differentiation status of the lung cancers (well versus moderately or poorly, P = 0.0439), whereas the deletion mutants were not.
|
15837743 |
2005 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Using the LightCycler PCR assay, the EGFR L858R mutation status might correlate with gender, pathologic subtypes, and gefitinib sensitivity of lung cancers.
|
15837743 |
2005 |
Adenocarcinoma, metastatic
|
|
0.010 |
GeneticVariation
|
BEFREE |
Our patient supports the proposition that somatic mutation L858R in exon 21 of the EGFR gene accounts for complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung.
|
16027522 |
2005 |
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Exogenous expression of either the L858R point mutant or the DeltaE746-E750 deletion mutant form of EGFR in immortalized human bronchial epithelial cells, p53 WT NSCLC (A549), or p53-null NSCLC (NCI-H1299) resulted in dramatically increased sensitivity to IR.
|
17018617 |
2006 |
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Mutations of the epidermal growth factor receptor (EGFR), particularly deletional mutations (DEL) in exon 19 and L858R in exon 21, are reportedly correlated with clinical outcome in patients with non-small cell lung cancer (NSCLC) receiving the EGFR tyrosine kinase inhibitors gefitinib and erlotinib, suggesting that detection of EGFR mutations would have an important role in clinical decision making.
|
16938658 |
2006 |
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Patients with NSCLC and EGFR exon 19 deletions have a longer survival following treatment with gefitinib or erlotinib compared with those with the L858R mutation.
|
16818686 |
2006 |
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The mutations consisted of the recurrent missense L858R and in-frame deletion delE746-A750, previously characterized as activating EGFR mutations in non-small cell lung cancer.
|
16857803 |
2006 |
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
EGFR mutations (CTG; CGG; L858R) were found from 63 of 575 lung cancer patients.
|
16890322 |
2006 |
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
EGFR mutations (CTG-->CGG; L858R) were found from 14 of 95 lung cancer patients.
|
16003726 |
2006 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Two weeks after induction with doxycycline, mice that express the EGFR(L858R) allele show diffuse lung cancer highly reminiscent of human bronchioloalveolar carcinoma and later develop interspersed multifocal adenocarcinomas.
|
16705038 |
2006 |
Adenocarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Two weeks after induction with doxycycline, mice that express the EGFR(L858R) allele show diffuse lung cancer highly reminiscent of human bronchioloalveolar carcinoma and later develop interspersed multifocal adenocarcinomas.
|
16705038 |
2006 |
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Two weeks after induction with doxycycline, mice that express the EGFR(L858R) allele show diffuse lung cancer highly reminiscent of human bronchioloalveolar carcinoma and later develop interspersed multifocal adenocarcinomas.
|
16705038 |
2006 |
Adenocarcinoma of lung (disorder)
|
|
0.100 |
GeneticVariation
|
BEFREE |
A simple and rapid method to detect the epidermal growth factor receptor hot spot mutation L858R in lung adenocarcinoma was developed based on principles similar to the universal heteroduplex generator technology.
|
16931592 |
2006 |
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
EGFR mutations (CTG; CGG; L858R) were found from 63 of 575 lung cancer patients.
|
16890322 |
2006 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
EGFR mutations (CTG-->CGG; L858R) were found from 14 of 95 lung cancer patients.
|
16003726 |
2006 |
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
EGFR mutations (CTG-->CGG; L858R) were found from 14 of 95 lung cancer patients.
|
16003726 |
2006 |
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
The EGFR mutation status, especially L858R mutation might be correlated with the clinico-pathological features related to good response to gefitinib, such as gender, smoking history, and pathological subtypes of Japanese lung cancers.
|
16890322 |
2006 |
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Two weeks after induction with doxycycline, mice that express the EGFR(L858R) allele show diffuse lung cancer highly reminiscent of human bronchioloalveolar carcinoma and later develop interspersed multifocal adenocarcinomas.
|
16705038 |
2006 |
Bronchioloalveolar Adenocarcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Two weeks after induction with doxycycline, mice that express the EGFR(L858R) allele show diffuse lung cancer highly reminiscent of human bronchioloalveolar carcinoma and later develop interspersed multifocal adenocarcinomas.
|
16705038 |
2006 |
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Although most EGFR mutations detected are short deletions in exon 19 or the L858R point mutation in exon 21, more than 75 different EGFR kinase domain residues have been reported to be altered in NSCLC patients.
|
17877814 |
2007 |
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
HRMA is a precise method for detecting DEL and L858R mutations and is useful for predicting clinical outcomes in patients with advanced NSCLC treated with gefitinib.
|
17875767 |
2007 |
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Three NSCLC cell lines with varying EGFR mutation status and sensitivities to EGFR-TKIs were selected: H3255 (L858R), H1650 (del E746-A750), and H1781 (wild-type EGFR).
|
17948911 |
2007 |